Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07555041
Completed Observational

Correlation Between Capillary Refill Time and Perfusion Index in Critically Ill Patients

NCT07555041 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-04-29
Last updated
2026-10-02

Condition(s) studied

Shock StateHemodynamics InstabilityMicrocirculationMonitoring

Investigational drug(s) / intervention(s)

Microcirculation monitoringMicrocirculation monitoring

Microcirculation monitoring: Microcirculation monitoring by Capillary Refill Time (CRT) measurements

Microcirculation monitoring: Microcirculation monitoring by Perfusion Index (PI) measurements

Study summary

Assessment of capillary refill time (CRT) is a cornerstone of tissue perfusion monitoring in critically ill patients.

CRT measurement is performed by applying brief and gentle pressure (for a few seconds) to a small area of skin until blanching occurs. CRT is defined as the time, in seconds, required for the skin surface to return to its initial color after release of pressure.

Although CRT is a monitoring tool used on a daily basis in emergency departments and critical care units, its practical measurement modalities remain poorly standardized and time-consuming. Consequently, there is no consensus regarding the most reproducible bedside method for CRT assessment. Moreover, repeated CRT measurements during patient management are resource-intensive in terms of medical time and may raise issues related to healthcare staff availability.

The perfusion index (PI) is a marker of tissue perfusion derived from a pulse oximetry sensor. This monitoring device is routinely used in all critically ill patients. It is placed on the finger and worn continuously, including during patient transport.

Because PI measurement is automatic and continuous, establishing its correlation with CRT could allow for more precise tissue perfusion monitoring while reducing the time burden associated with bedside assessments in critically ill patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria : * Adult patient. * Admission within the previous 24 hours, or within 24 hours of the onset of a hemodynamic instability criterion (requirement for vasopressors or fluid resuscitation). * Absence of patient objection. Exclusion criteria : * Legal guardianship, curatorship, or judicial protection. * No social security coverage. * Morphological abnormalities preventing CRT and IP measurements.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Service de Réanimation cardio-vasculaire et thoracique, Hôpital Cardiologique louis Pradel, Hospices Civils de Lyon Bron France
Service de Médecine Intensive-Réanimation, Hôpital Édouard Herriot, Hospices Civils de Lyon Lyon France

More Hospices Civils de Lyon trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07555041 on ClinicalTrials.gov ↗ ← All trials in France